Patients with multiple myeloma who relapse after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy may benefit from “subsequent T-cell redirection,” according to researchers.
The findings support clinical trials investigating the sequence of T-cell-engaging therapies to optimize outcomes for patients with multiple myeloma, Samir Parekh, MD, director of translational research in multiple myeloma and co-leader of the Cancer Clinical Investigation program at The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai, told Healio. It was the top
